课题基金 / 基金详情

Inflammatory response to sleep apnea in obese subjects

Inflammatory response to sleep apnea in obese subjects
肥胖受试者对睡眠呼吸暂停的炎症反应
批准号:
7864103
负责人:
JULIO ALONSO CHIRINOS MEDINA
金额:
$60.35万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2006
资助国家:
美国
项目状态:
已结题
起止时间:
2006-05-22 至 2013-04-30

项目摘要

项目成果

JULIO ALONSO CHIRINOS MEDINA的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Obstructive sleep apnea (OSA) is associated with an increased risk for cardiovascular events. Whether the mechanism for this association is directly attributable to pro-atherosclerotic effects of OSA or primarily related to obesity is not known. Obesity is common in patients with OSA, and is itself associated with an inflammatory state and insulin resistance. In individuals with both obesity and OSA, the repetitive hypoxia associated with OSA may promote inflammation and insulin resistance. Our primary aim is to test the hypothesis that OSA plays a primary role in the inflammatory state of patients with obesity and moderate-severe OSA, and that therefore the elimination of apnea by continuous positive airway pressure (CPAP) therapy in these patients will more greatly reduce inflammation (measured by C-reactive protein or CRP) than weight loss alone, and that combining these two therapies will have additive effects on reducing inflammation.; Our second aim is to test the hypothesis that OSA and obesity independently contribute to the insulin resistant state in these patients, and thus combined weight loss and CPAP therapy will have greater effects on lowering insulin resistance than either therapy alone. Our third aim is to test the hypothesis that OSA and obesity contribute independently to vascular endothelial dysfunction, through their effects on inflammation and insulin resistance, and that therefore combining weight loss and CPAP therapy will improve endothelial function more than either therapy alone. To address these aims, we plan to randomize 201 subjects with obesity and moderate-severe OSA, and baseline CRP>1.0 mg/L to 1) weight loss theYapy alone; 2) CPAP therapy alone; or 3) weight loss plus CPAP therapy for 6 months. We will measure CRP, insulin resistance (area under the curve of a glucose tolerance test), and endothelial function (by brachial artery flow studies) at baseline, and weeks 6, 12, and 24. We propose that this study design will provide the best way to separate the independent effects of obesity and OSA on cardiovascular risk.
期刊论文(7)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1016/j.artres.2012.12.002
发表时间: 2013-03
期刊: ARTERY RESEARCH
影响因子: 0.6
作者: [Chirinos, Julio A]
通讯作者: Chirinos, Julio A
Low-carbohydrate diets, obesity, and metabolic risk factors for cardiovascular disease.
低碳水化合物饮食、肥胖和心血管疾病的代谢危险因素。
DOI: 10.1007/s11883-007-0059-7
发表时间: 2007
期刊: Current atherosclerosis reports
影响因子: 5.8
作者: [Samaha,FrederickF, Foster,GaryD, Makris,AngelaP]
通讯作者: Makris,AngelaP
DOI: 10.2337/dc09-2353
发表时间: 2010-06
期刊: Diabetes care
影响因子: 16.2
作者: [Medina-Lezama J, Pastorius CA, Zea-Diaz H, Bernabe-Ortiz A, Corrales-Medina F, Morey-Vargas OL, Chirinos DA, Muñoz-Atahualpa E, Chirinos-Pacheco J, Chirinos JA, PREVENCION Investigators]
通讯作者: PREVENCION Investigators
DOI: 10.1007/s10865-017-9869-4
发表时间: 2017-12
期刊: JOURNAL OF BEHAVIORAL MEDICINE
影响因子: 3.1
作者: [Chirinos, Diana A, Gurubhagavatula, Indira, Broderick, Preston, Chirinos, Julio A, Teff, Karen, Wadden, Thomas, Maislin, Greg, Saif, Hassam, Chittams, Jesse, Cassidy, Caitlin, Hanlon, Alexandra L, Pack, Allan I]
通讯作者: Pack, Allan I
Cardiovascular Risk, Vascular and Kidney Damage in COVID-19 Survivors
  • 批准号:
    10364096
  • 项目类别:
  • 资助金额:
    $80.33万
  • 财政年份:
    2022
  • 负责人:
    JULIO ALONSO CHIRINOS MEDINA
  • 依托单位:
Cardiovascular Risk, Vascular and Kidney Damage in COVID-19 Survivors
  • 批准号:
    10553207
  • 项目类别:
  • 资助金额:
    $79.23万
  • 财政年份:
    2022
  • 负责人:
    JULIO ALONSO CHIRINOS MEDINA
  • 依托单位:
Genetic determinants of thoracic aortic stiffness and remodeling
  • 批准号:
    10322755
  • 项目类别:
  • 资助金额:
    $19.5万
  • 财政年份:
    2021
  • 负责人:
    JULIO ALONSO CHIRINOS MEDINA
  • 依托单位:
Efficacy of Fenofibrate for COVID-19: A phase II randomized controlled trial
  • 批准号:
    10245967
  • 项目类别:
  • 资助金额:
    $132.83万
  • 财政年份:
    2021
  • 负责人:
    JULIO ALONSO CHIRINOS MEDINA
  • 依托单位:
海外基金